Title: Reduction of Cell-Cell Communication in Prostate Cancer Using STEAP-1 siRNA
Patent Number: 7,939,503
Filed: June 4, 2004
Lead Inventor: Aya Jakobovits, Agensys
The patent, its abstract states, claims "antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof ... wherein STEAP-1 exhibits tissue-specific expression in normal adult tissue, and is aberrantly expressed in [certain] cancers listed. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic, and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization."
Title: RNAi Inhibition of Alpha-ENaC Expression
Patent Number: 7,939,508
Filed: April 30, 2010
Lead Inventor: Gino Van Heeke, Novartis
"The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides," the patent's abstract states.
Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
Patent Number: 7,939,652
Filed: Feb. 28, 2008
Lead Inventor: Orna Mor, Quark Pharmaceuticals
"The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human TGaseI gene at the post-transcriptional level," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier."
The invention also comprises "a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis, or ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient," the abstract adds. "The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseI polypeptide."
Title: Sensitization of Cancer Cells to Therapy Using siNA Targeting Genes for the 1p and 19q Chromosomal Regions
Patent Number: 7,939,653
Filed: July 23, 2007
Lead Inventor: Francois Berger, Joseph Fourier University
"The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules [that] inhibit the expression of these genes by RNA interference, and to their use as adjuvant in cancer therapy to sensitize cancer cells to conventional anticancer agents," according to the patent's abstract.
Title: Oligomeric Compounds Comprising 4'-Thionucleosides for Use in Gene Modulation
Patent Number: 7,939,677
Filed: Aug. 31, 2010
Lead Inventor: Balkrishen Bhat, Isis Pharmaceuticals
The invention "provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation," the patent's abstract states. "The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification."
Title: microRNA Motifs
Patent Number: 7,941,278
Filed: Dec. 28, 2006
Lead Inventor: Yu-Ching Chang, Industrial Technology Research Institute
The invention, the patent's abstract states, comprises "methods of identifying microRNA motifs or microRNA precursors for a target gene or a set of target genes. Also disclosed are related computer-readable media."
Title: siRNA Targeting TNFa
Application Number: 20110105363
Filed: Dec. 23, 2010
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNF.alpha."
Title: Method of Using miR-34 as a Biomarker for TP53 Functional Status
Application Number: 20110105583
Filed: May 5, 2008
Lead Inventor: Michele Cleary, Merck
"The invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell," the patent application's abstract states. "In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer."
Title: RTP-801L siRNA Compounds and Methods of Use Thereof
Application Number: 20110105584
Filed: Dec. 11, 2008
Lead Inventor: Elena Feinstein, Quark Pharmaceuticals
"The invention provides chemically modified siRNA oligonucleotides that target RTP-801L, compositions comprising same, and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments," the patent application's abstract states.
Title: siRNA Compounds for Inhibiting NRF2
Application Number: 20110105591
Filed: April 6, 2009
Lead Inventor: Elena Feinstein, Quark Pharmaceuticals
The invention "provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers," according to the patent application's abstract.
Title: microRNA-Formatted Multi-Target Interfering RNA Vector Constructs and Methods of Using the Same
Application Number: 20110105593
Filed: June 3, 2010
Lead Inventor: Laura Steel, Drexel University
The invention, the patent application's abstract states, comprises "vectors expressing multiple microRNA-formatted interfering RNAs from a single transcript ... and methods of using the same to inhibit expression of one or more target genes."